A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants With Atopic Keratoconjunctivitis (AKC)
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. Approximately 138 participants who meet all eligibility criteria will be enrolled in the study.
∙ Participants are eligible to be included in the study only if all of the following criteria apply:
• Men or women aged ≥ 18 and ≤ 65 years of age.
• Diagnosis of AKC in both eyes, including the presence or medical history of the following:
‣ other atopic condition (ie,. atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
⁃ chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
• Ocular itching of at least 50 as assessed by VAS scale.
• Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
• A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
• If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.